Devonian Health Group Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Luc Gregoire

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

Does Devonian Health Group's (CVE:GSD) CEO Salary Compare Well With Industry Peers?

Mar 02

CEO

Luc Gregoire (64 yo)

less than a year

Görev süresi

Mr. Luc D. Grégoire, CPA, CA, served as Independent Director at Devonian Health Group Inc. since March 17, 2023 until December 04, 2023. He serves as President, CEO and Director of Devonian Health Group In...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Andre Boulet	Chair of the Board	9.7yrs	CA$644.63k	0.057% CA$ 11.4k
Luc Gregoire	President	less than a year	Veri yok	Veri yok
Colette Laurin	Interim CFO	8.9yrs	CA$181.61k	0.022% CA$ 4.5k

2.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: GSD 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Andre Boulet	Chair of the Board	9.7yrs	CA$644.63k	0.057% CA$ 11.4k
Luc Gregoire	President	1.7yrs	Veri yok	Veri yok
George Zhanel	Member of Scientific Advisory Board	5.3yrs	Veri yok	Veri yok
David Baker	Independent Director	1.5yrs	Veri yok	Veri yok
Louis Flamand	Member of Scientific Advisory Board & Independent Director	7.5yrs	CA$4.00k	Veri yok
John Trant	Member of Scientific Advisory Board	5.6yrs	Veri yok	Veri yok
Francois Malouin	Member of Scientific Advisory Board	5.6yrs	Veri yok	Veri yok
Suha Jabaji	Member of Scientific Advisory Board	5.6yrs	Veri yok	Veri yok
Sam Hanna	Member of Clinical Dermatology Advisory Board	5.2yrs	Veri yok	Veri yok
Ian D. Landells	Member of Clinical Dermatology Advisory Board	5.2yrs	Veri yok	Veri yok
Jaggi Rao	Member of Clinical Dermatology Advisory Board	5.2yrs	Veri yok	Veri yok
Jerry Tan	Member of Clinical Dermatology Advisory Board	5.2yrs	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GSD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Devonian Health Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Devonian Health Group Inc. Announces the Resignation of Colette Laurin as Interim Chief Financial Officer, Effective January 5, 2025

Devonian Health Group Inc. Appoints André P. Boulet to Chairman of the Board and Chief Operating Officer

Devonian Health Group Inc., Annual General Meeting, Feb 20, 2024

Devonian Health Group Inc. Announces CEO Changes

Devonian Health Group Announces the Appointment of New Board Members

Devonian Health Group Inc., Annual General Meeting, Mar 17, 2023

Recent updates

Devonian Health Group Inc. Announces the Resignation of Colette Laurin as Interim Chief Financial Officer, Effective January 5, 2025

Third quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.011 loss in 3Q 2023)

Devonian Health Group Inc. Appoints André P. Boulet to Chairman of the Board and Chief Operating Officer

Second quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.008 loss in 2Q 2023)

Devonian Health Group Inc. announced that it has received CAD 0.2238 million in funding

Devonian Health Group Inc., Annual General Meeting, Feb 20, 2024

Devonian Health Group Inc. Announces CEO Changes

Full year 2023 earnings released: CA$0.034 loss per share (vs CA$0.026 loss in FY 2022)

Devonian Health Group Inc. Files Patent Cooperation Treaty (PCT) Application for Thykamine™? in Wound Healing

Devonian Health Group Inc. announced that it has received CAD 0.5 million in funding

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.006 loss in 3Q 2022)

Devonian Health Group Inc. announced that it has received CAD 1.199665 million in funding

Devonian Health Group Inc. announced that it expects to receive CAD 5 million in funding

Devonian Health Group Announces Presentation of ThykamineTM Efficacy Results in Atopic Dermatitis at the World Congress of Dermatology and Provides ThykamineTM Clinical Development Program Update

Devonian Health Group Announces the Appointment of New Board Members

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.01 loss in 2Q 2022)

Is Devonian Health Group (CVE:GSD) A Risky Investment?

Devonian Health Group Inc., Annual General Meeting, Mar 17, 2023

Devonian Health Group Inc. Announces Executive Changes

Is Devonian Health Group (CVE:GSD) Using Debt In A Risky Way?

Full year 2022 earnings released

High number of new directors

Devonian Health Group Inc. to Present ThykamineTM Phase 2 Clinical Results at the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases

Devonian Health Group Announces Peer-Reviewed Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Journal of Drugs in Dermatology

High number of new directors

Devonian Health Group Inc. Announces CEO Changes

Is Devonian Health Group (CVE:GSD) Weighed On By Its Debt Load?

Third quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.01 loss in 3Q 2021)

High number of new directors

Devonian Health Group Announces the Journal of Drugs in Dermatology Acceptance for Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Atopic Dermatitis

High number of new directors

Does Devonian Health Group (CVE:GSD) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: CA$0.01 loss per share (vs CA$0.01 loss in 2Q 2021)

High number of new and inexperienced directors

Devonian Health Group Inc. Approves Board Appointments

Devonian Health Group Inc. announced that it has received CAD 10.034299 million in funding

Full year 2021 earnings: Revenues in line with analyst expectations

Devonian Health Group Inc. announced that it has received CAD 1.06264 million in funding

Third quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.014 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.019 loss in 2Q 2020)

Does Devonian Health Group's (CVE:GSD) CEO Salary Compare Well With Industry Peers?

Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of ThykamineTM in Adult Patients with Mild-to-Moderate Atopic Dermatitis

New 90-day high: CA$0.29

Devonian Health Group Inc. Appoints Erick Shield as Director

New 90-day high: CA$0.28

Devonian Health Group Inc. announced that it has received CAD 1.212 million in funding

Devonian Health Group Inc., Annual General Meeting, Jan 27, 2021

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş